Lycia Therapeutics' Sofia Touami reports stock options

Each option has a separate vesting schedule tied to continued service, and the reported expiration dates range from 2033 to 2036.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. (LYCA) Chief Business Officer Sofia Touami reported direct holdings of options to buy common stock: 169,228 shares at a $1.67 exercise price, expiring August 13, 2033; 94,262 shares at $2.44, expiring June 27, 2034; and 68,755 shares at $3.70, expiring August 10, 2036. Each option's vesting is subject to her service on each vesting date.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Touami Sofia

Role Chief Business Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) ^F1	--	--	--
holding	Stock Option (Right to Buy) ^F2	--	--	--
holding	Stock Option (Right to Buy) ^F3	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 332,245 contracts (Direct)

Footnotes (3)

F1. The options vested as to 1/4 of the total award on July 10, 2024, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Shares subject to option: 169,228 shares Option exercise price: $1.67 per share Shares subject to option: 94,262 shares +3 more

6 metrics

Shares subject to option 169,228 shares Exercise price $1.67; expires August 13, 2033

Option exercise price $1.67 per share Option covering 169,228 common shares

Shares subject to option 94,262 shares Exercise price $2.44; expires June 27, 2034

Option exercise price $2.44 per share Option covering 94,262 common shares

Shares subject to option 68,755 shares Exercise price $3.70; expires August 10, 2036

Option exercise price $3.70 per share Option covering 68,755 common shares

Key Terms

Stock Option (Right to Buy), vest monthly, vesting date

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest monthly financial

"an additional 1/48 of the total award will vest monthly thereafter"

vesting date financial

"on each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What LYCA options did Sofia Touami report?

Sofia Touami reported direct options covering 169,228 common shares at $1.67, 94,262 at $2.44, and 68,755 at $3.70. Their expiration dates are August 13, 2033, June 27, 2034, and August 10, 2036, respectively.

How do Sofia Touami's LYCA options vest?

The option covering 169,228 shares vested as to 1/4 on July 10, 2024, with an additional 1/48 vesting monthly; the 94,262-share option vested as to 1/48 on July 27, 2024, with an additional 1/48 monthly; and the 68,755-share option vested as to 1/48 on September 6, 2026, with an additional 1/48 monthly. Each schedule is subject to her service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/24/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/22/2026 - 07:16 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Touami Sofia

(Last)

(First)

(Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2026

3. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	08/13/2033	Common Stock	169,228	$1.67	D
Stock Option (Right to Buy)	⁽²⁾	06/27/2034	Common Stock	94,262	$2.44	D
Stock Option (Right to Buy)	⁽³⁾	08/10/2036	Common Stock	68,755	$3.7	D

Explanation of Responses:

1. The options vested as to 1/4 of the total award on July 10, 2024, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR